vimarsana.com

Page 170 - ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SQI Diagnostics Announces New Corporate Website

SQI Diagnostics Announces New Corporate Website News provided by Share this article New Website Provides Essential Information on Company s Strategic Initiative TORONTO, Feb. 18, 2021 /PRNewswire/ - SQI Diagnostics Inc. (the Company or SQI ) (TSX-V: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today is proud to announce the launch of its newly redesigned website at https://www.sqidiagnostics.com. The revamped site features a streamlined, modern design, improved functionality and easy access to essential information to help educate all stakeholders about the Company and its new strategic vision, including the latest product development and investor information.  

Provention Bio to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Provention Bio to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 - Company also Announces Presentation at the 2021 SVB Leerink Global Healthcare Conference - News provided by Share this article Share this article RED BANK, N.J., Feb. 18, 2021 /PRNewswire/  Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2020 financial results on February 25, 2021 before the opening of the U.S. financial markets.  Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.

Medicine-On-Time Installs New Printing Press in Anticipation of 2021 Growth

Share this article Share this article THONOTOSASSA, Fla., Feb. 18, 2021 /PRNewswire/  CSS Health s Pharmacy Services Division (aka Medicine-On-Time) announces today the installation of its new Gonderflex printing press for medication adherence compliance packaging, which expands their manufacturing capacity for anticipated growth in 2021.   Medication Adherence continues to be a driving force to improve population health, reduce overall healthcare costs and achieve better health outcomes in the United States healthcare system.  Pharmacies are using more compliance packaging to meet these goals. We purchased the press from Gonderflex International in Montreal, Canada. The manufacturing of compliance packaging requires high quality printing, unique to the industry. The Gonderflex prints, die cuts and laminates paper / foil barriers to produce a high-quality compliance packaging, meeting the most stringent requirements to achieve class B packaging standards recognized by t

Widex US Names Retail Branding Veteran Kerrie Coughlin Vice President of Marketing

Widex US Names Retail Branding Veteran Kerrie Coughlin Vice President of Marketing News provided by Share this article Share this article HAUPPAUGE, N.Y., Feb. 18, 2021 /PRNewswire/  Widex US Inc. today announced the appointment of Kerrie Coughlin as Vice President of Marketing, tapped to bolster the Widex brand to its core audiologist and consumer audiences while further driving the success of Widex hearing solutions in the US market. A veteran of prominent retail brands, Coughlin reports to Sheena Oliver, Chief Marketing Officer of parent company WSA. In addition to overseeing the company s entire marketing and communications portfolio in the United States, Coughlin will support the rollout of several new Widex products designed to complement and enhance the popular WIDEX MOMENT hearing aids, first introduced in 2020.

CollPlant Issues Letter to Shareholders

CollPlant Issues Letter to Shareholders USA - English Expansion of collaboration with United Therapeutics to cover a second lifesaving organ, human kidneys, in addition to lungs Development and commercialization agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen to be used in dermal and soft tissue filler products Growing revenues and strong cash position, allowing execution of our strategic plan News provided by Share this article Share this article REHOVOT, Israel, Feb. 18, 2021 /PRNewswire/ CollPlant Biotechnologies (NASDAQ: CLGN) today announced the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders. Dear shareholders, Dermal filler treatment BioInk development

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.